---
title: "【New Stock Listing】MICOT PHARMA surges 100%, earning HKD 3,740 for a single lot"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290669977.md"
description: "Two new stocks were listed today (24th) with good prices. Among them, the intelligent robotics company SEER TECH, which \"dived\" in the dark market yesterday (23rd), opened at HKD 101.6, flat with the offer price, and later peaked at HKD 140.5, closing at HKD 106, up 4.3% from the offer price. Each board lot is 50 shares, and excluding fees, the paper profit per lot is about HKD 220. As for the biotechnology company MICOT PHARMA-B, it opened at HKD 34.02, up over 86% from the offer price of HKD 18.2, and later reached a high of HKD 37.1, closing at HKD 36.9, more than double the offer price. Each board lot is 200 shares, and excluding fees, the paper profit per lot is about HKD 3740"
datetime: "2026-06-24T09:07:53.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290669977.md)
  - [en](https://longbridge.com/en/news/290669977.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290669977.md)
---

# 【New Stock Listing】MICOT PHARMA surges 100%, earning HKD 3,740 for a single lot

【Now 新聞台】兩隻新股今日 (24 日) 首日掛牌，股價造好。

其中，昨日 (23 日) 暗盤「潛水」的智能機械人公司仙工智能，開市報 101.6 元，跟招股價持平，其後一度高見 140.5 元，收市報 106 元，高招股價 4.3%，每手 50 股，不計手續費，每手帳面賺約 220 元。

至於生物技術公司麥科醫藥開市報 34.02 元，較招股價 18.2 元，高逾 86%，之後曾高見 37.1 元，收市報 36.9 元，高招股價逾 1 倍，每手 200 股，不計手續費，每手帳面賺約 3740 元。

### Related Stocks

- [02335.HK](https://longbridge.com/en/quote/02335.HK.md)
- [06106.HK](https://longbridge.com/en/quote/06106.HK.md)

## Related News & Research

- [CMB International leads XianGong Intelligent HK$ 1.07 billion Hong Kong IPO](https://longbridge.com/en/news/290654311.md)
- [Everest Medicines enters China commercialization collaboration with Hainan Herui for budesonide enteric capsules](https://longbridge.com/en/news/290642767.md)
- [18:54 ETAbu Dhabi Opens Strategic Life Sciences Corridor to California Through Biocom Partnership](https://longbridge.com/en/news/290616206.md)
- [Transgene posts investor presentation on individualized neoantigen cancer vaccine platform](https://longbridge.com/en/news/290810890.md)
- [Sino Biopharm says China regulator accepts LM-302 gastric cancer drug application for priority review](https://longbridge.com/en/news/290533506.md)